טוען...
Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosis
BACKGROUND: The mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene results in CF. The most common mutation, ΔF508-CFTR, is a temperature-sensitive, trafficking mutant with reduced chloride transport and exaggerated immune response. The ΔF508-CFTR is misfolded, ubiquitina...
שמור ב:
| Main Authors: | , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2954907/ https://ncbi.nlm.nih.gov/pubmed/20868490 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1477-3155-8-22 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|